Stifel Nicolaus Lowers Nyxoah (NASDAQ:NYXH) Price Target to $19.00

Nyxoah (NASDAQ:NYXH) had its price objective dropped by Stifel Nicolaus from $27.00 to $19.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 139.07% from the company’s current price.

Other equities research analysts also recently issued research reports about the stock. Oppenheimer reduced their target price on shares of Nyxoah from $20.00 to $15.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 15th. HC Wainwright reduced their price target on shares of Nyxoah from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, May 24th. Piper Sandler upped their price target on shares of Nyxoah from $15.00 to $20.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. Finally, Cantor Fitzgerald reduced their price target on shares of Nyxoah from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 15th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Nyxoah currently has a consensus rating of “Moderate Buy” and an average target price of $17.80.

Nyxoah Stock Performance

Shares of NASDAQ:NYXH opened at $7.95 on Monday. Nyxoah has a 52 week low of $4.00 and a 52 week high of $20.00. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.70 and a current ratio of 3.94. The company’s fifty day moving average is $9.29 and its 200-day moving average is $9.81.

Nyxoah (NASDAQ:NYXH) last issued its earnings results on Tuesday, May 14th. The company reported ($0.45) EPS for the quarter, meeting the consensus estimate of ($0.45). Nyxoah had a negative net margin of 843.49% and a negative return on equity of 42.14%. The company had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.20 million. On average, equities analysts forecast that Nyxoah will post -1.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nyxoah stock. Ikarian Capital LLC acquired a new position in shares of Nyxoah S.A. (NASDAQ:NYXH) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 50,699 shares of the company’s stock, valued at approximately $684,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.